VC / HealthTech / MedTech / BioTech: Pureos Bioventures expands fund size to USD 205 million

Pureos Bioventures expands fund size to USD 205 million

Exclusive focus on innovative drug development companies
Global investment scope with an emphasis on Switzerland and Europe
Team with deep expertise in investing, company building and drug development
First ten investments and a first IPO exit completed

Pureos Bioventures announces the final closing of its first fund BB Pureos Bioventures LP (“Pureos”) with a committed capital of USD 205 million. Pureos will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, celland gene therapies. The fund’s portfolio companies are built on scientific excellence with strong teams to develop therapies across a broad spectrum of indications including oncology, immunology, ophthalmology, rare diseasesand neuroscience. The fund invests globally, with a primary focus on Switzerland and Europe. The Pureos team consists of experienced venture capitalists, biotech entrepreneursand drug developers. With its committed capital, Pureos is the largest institutional Swiss VC fund that solely invests in private biotech companies. For its first fund, Pureos is building a balanced portfolio of 1720 preclinical and clinicalstage companies. Its initial investments include Alentis Therapeutics AG, AMPharma BV, Araris AG, Corlieve Therapeutics SAS, Eyevensys SAS, Imcheck Therapeutics SAS, Lava Therapeutics BV, NovaGo Therapeutics AG, River Renal Corp and Vico Therapeutics BV. In addition, Pureos is a Partner of Base Launch, a startup accelerator in Basel that supports emerging companies with groundbreaking science. In March, Lava Therapeutics went public on NASDAQ (LVTX), representing a first IPO exit in the Pureos portfolio.
Pureos’ partners Klaus Breiner, Dominik Escher, Anja Harmeier, and Martin Münchbach stated: “We are extremely pleased with the successful final closing of our first fund with an amountabove our initial target. With the entrusted monies, we want to continue to support great teams developing innovative therapeutics for devastating diseases that make a true difference for patients. Our first IPO validates this strategy also from a return perspective for our investors.
The supporters of the first Pureos fund include strategic partners, such as pharmaceutical and biotech companies as well as a large contract manufacturer, family offices, pension funds, fundoffunds and other institutional investors.

About Pureos Bioventures
Pureos Bioventures is a newly formed venture capital fund, advised by Bellevue Asset Management. Pureos invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built ateam with deep investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases.

For more information visit


Logo (c) Pureos Bioventures

VC / HealthTech / MedTech: Endeavour Vision closes Endeavour Medtech Growth II LP at USD 375m
BioTech: PreComb Therapeutics AG schließt 2.2 Mio CHF Seed-Finanzierung ab, es investieren Kinled Austria, HTGF, FiveT Capital und weitere

Ähnliche Beiträge